^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Urothelial Cancer

    Related cancers:
    1d
    A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=3000, Not yet recruiting, Pfizer
    New trial • HEOR • Real-world evidence
    1d
    ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Steba Biotech S.A. | Trial primary completion date: Jun 2025 --> Mar 2026
    Trial primary completion date
    |
    Tookad (padeliporfin)
    1d
    Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma. (PubMed, Appl Immunohistochem Mol Morphol)
    CCL8 has the potential to be a prognostic biomarker, aiding in patient stratification and treatment planning. Further multicenter studies with longer follow-up periods and functional validation are required to confirm these findings and fully understand the role of CCL8 in urothelial carcinoma.
    Journal
    |
    CCL8 (C-C Motif Chemokine Ligand 8)
    2d
    Innovative imaging techniques for urothelial carcinoma (PubMed, Urologie)
    For local staging of urothelial carcinoma, mpMRI-or, in selected cases, bpMRI-should preferably be performed prior to transurethral resection of the bladder tumor (TUR-B) according to VI-RADS standards. Only in selected cases is FDG-PET/CT to be used for N/M staging and restaging. Targeted imaging (e.g., NECTIN-4) and artificial intelligence (AI) are still in the research phase, whereby prospective trials with decision-impact outcomes and standardized implementation and quality processes have priority.
    Review • Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    3d
    Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=280, Recruiting, SystImmune Inc. | Trial completion date: Aug 2027 --> Apr 2029 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression
    |
    trastuzumab brengitecan (BL-M07D1)
    3d
    Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer models. (PubMed, Mol Ther Oncol)
    Together, reoviruses display strong oncolytic properties in preclinical UCB models. jin-3 reoviruses elicit robust immunostimulatory responses, highlighting their potential as candidate agents for clinical translation in UCB.
    Preclinical • Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    4d
    Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (clinicaltrials.gov)
    P3, N=486, Recruiting, NRG Oncology | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> May 2026
    Enrollment open • Trial initiation date
    |
    cisplatin • gemcitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    4d
    Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation. (PubMed, Case Rep Hematol)
    An increased prevalence of second primary malignancy is anticipated due to the rising cancer burden and the careful screening of index initial malignancy throughout therapy. Determining the best course of action requires careful staging of the cancer and discussion by a multidisciplinary team.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    5d
    Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2030 --> Jul 2031 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    CIML NK
    5d
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=204, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    5d
    BLC2001: An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer (clinicaltrials.gov)
    P2, N=239, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Mar 2027
    Trial completion date
    |
    Balversa (erdafitinib) • metformin • midazolam hydrochloride